The release of updated international pharmacopoeia standards in early 2026 marks a decisive turning point for cardiac pharmaceutical quality control. With new monographs addressing anti-arrhythmic drugs and biological implants, health ministries are tightening the belt on purity and bioequivalence. This move is designed to bolster global trust in manufactured treatments, ensuring standardized...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek